Commercialization
Gilead takes a ‘different’ approach to reaching the Black community with new HIV campaign
Following the FDA approval of the long-acting HIV prevention drug Yeztugo, Gilead Sciences faces the challenge of reaching populations with lower PrEP usage. The company launches a new ad campaign called 'Up to Date,' partnering with comedians Nicole Byer and Devon Walker, using humor and real dating scenarios to drive conversations about HIV prevention in Black communities. This campaign is a continuation of 'Care for the Culture,' led by Black creators, aiming to reduce stigma and promote health equity through authentic storytelling.
Drugs that missed the mark in pharma’s last earnings round
Even blockbuster drugs can disappoint investors. In the latest earnings season, Alnylam's Amvuttra, AbbVie's Imbruvica, Merck's vaccine portfolio, and Roche's Vabysmo all fell short of consensus estimates, each for distinct reasons ranging from demand normalization to policy shifts and market competition.
Brand-name drug denials are surging, especially for weight-loss
A new study published in JAMA shows that between 2018 and 2024, formulary-based denial rates for brand-name drugs rose by 67%, with weight-loss drugs having an initial approval rate of only 14.8%. The study analyzed over 2 million prescriptions from 1.17 million people and found that nearly one-third of first fills were denied, and nearly half were not filled within 90 days. GLP-1 drugs had the highest absolute number of denials, but weight-loss drugs had higher denial rates.
Compounders maintain a firm grip on the GLP-1 market
A recent Gallup survey shows that nearly four times as many Americans use GLP-1 weight-loss drugs, but about 20% still use versions not approved by the FDA. Compounding pharmacies held about 30% of the market at their peak in 2024, and although the FDA removed semaglutide and tirzepatide from the shortage list and proposed excluding them from the 503B bulk list, compounding pharmacies still maintain their market presence through "personalized" versions. Novo Nordisk and Eli Lilly have taken legal and regulatory actions, but public demand for alternative weight-loss solutions remains strong.
AstraZeneca aims for a new blockbuster run in cardio disease
AstraZeneca is returning to the forefront of cardiovascular disease treatment with its first-in-class drug Baxfendy (baxdrostat). The drug was recently approved by the FDA for the treatment of resistant hypertension and is expected to become a new growth engine for the company in the cardiovascular, renal, and metabolic (CVRM) field. Company executives stated that Baxfendy's differentiated mechanism fills a more than two-decade innovation gap in this area, while the company is expanding its indications to chronic kidney disease, heart failure, and others, targeting peak annual sales of $5 billion.
Who’s winning pharma’s innovation race? The rankings are out.
Idea Pharma's latest Global Pharmaceutical Innovation and Invention Index shows that Eli Lilly topped both lists for the first time, driven by weight-loss drugs and pipeline investments; Novo Nordisk fell out of the top ten due to slowing growth and restructuring; Sanofi and GSK jumped significantly in rankings, while Pfizer and BMS slipped due to clinical setbacks. The list also featured, for the first time, 10 emerging biotech companies with disruptive potential.
Novo Nordisk Raises Full-Year Outlook: Oral Wegovy Gets Strong First-Quarter Sales Start
Novo Nordisk reported first-quarter results, with oral Wegovy sales reaching DKK 2.26 billion, far exceeding analyst expectations, prompting the company to raise its full-year guidance. Despite competition from Lilly and pricing pressures, the company expects the decline in adjusted sales and operating profit to narrow to 4%-12% in 2026.
Predictive analytics transforms laboratory data into pharmaceutical launch strategies
The pharmaceutical industry faces the challenge of high R&D investment and low approval rates, making the identification of patients and physicians during the commercialization phase critical. Parag More of Quest Diagnostics points out that predictive analytics based on laboratory results and claims can validate hypotheses, estimate market size, and optimize physician education, driving data-driven launch strategies.
FDA's 'Shaming Regulation' Sparks Industry Controversy: The Game Between Transparency and Trade Secrets
The U.S. Food and Drug Administration (FDA) is pursuing an 'aggressive transparency' strategy, placing regulatory actions against pharmaceutical companies under public scrutiny by releasing complete response letters (CRLs) in real time, attaching inspection photos to warning letters, and strictly penalizing false advertising. Although this approach has been welcomed by investors, industry experts point out that it may cause companies to lose control over the narrative of their new products, facing risks of data misinterpretation, stock price volatility, and legal liabilities.